Back to top
more

HeartBeam (BEAT)

(Delayed Data from NSDQ)

$2.36 USD

2.36
129,698

-0.05 (-2.07%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $2.35 -0.01 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (46 out of 249)

Industry: Medical Info Systems

Zacks News

BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know

BioTelemetry (BEAT) closed the most recent trading day at $67.54, moving -1.03% from the previous trading session.

Urmimala Biswas headshot

Encouraging Near-Term Outlook for Medical Services Industry

With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.

CareDx (CDNA) in Focus: Stock Moves 9.8% Higher

CareDx (CDNA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: First Western, CBIZ, BioTelemetry, Expeditors International and Core-Mark

The Zacks Analyst Blog Highlights: First Western, CBIZ, BioTelemetry, Expeditors International and Core-Mark

Zacks Market Edge Highlights: Tesla, BioTelemetary, Amazon, Booking and Nike

Zacks Market Edge Highlights: Tesla, BioTelemetary, Amazon, Booking and Nike

Tracey Ryniec headshot

Investing in the Innovation Winners

If only an investor could buy companies that were on the cutting edge. How do you find those stocks?

Tirthankar Chakraborty headshot

U.S. Service Sector Humming: 5 Solid Buys

The non-manufacturing index comes in at 59.7 in February, topping analysts' estimates of 57.3. It also sees uninterrupted expansion for the 109th consecutive month.

BioTelemetry (BEAT) Q4 Earnings and Revenues Top Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 33.33% and 0.57%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

BioTelemetry (BEAT) Dips More Than Broader Markets: What You Should Know

BioTelemetry (BEAT) closed at $76.01 in the latest trading session, marking a -0.38% move from the prior day.

BioTelemetry (BEAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioTelemetry (BEAT) Gains As Market Dips: What You Should Know

In the latest trading session, BioTelemetry (BEAT) closed at $73.52, marking a +0.05% move from the previous day.

BioTelemetry (BEAT) Upgraded to Buy: Here's Why

BioTelemetry (BEAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?

BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

BioTelemetry (BEAT) closed at $72.34 in the latest trading session, marking a +0.72% move from the prior day.

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.

NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y

NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.

Varian (VAR) Meets Q1 Earnings Estimates, Grows Globally

Solid overseas growth boosts Varian's (VAR) fiscal Q1 results.

PetMed (PETS) Q3 Earnings Fall Y/Y, Reorder Sales Strong

PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.

Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid

Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.

BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, BioTelemetry (BEAT) closed at $67.50, marking a +0.42% move from the previous day.

Top Ranked Momentum Stocks to Buy for January 23rd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 23rd:

Teladoc Expands Services with Virtual Back Pain Treatment

Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.

BioTelemetry (BEAT) is a Great Momentum Stock: Should You Buy?

Does BioTelemetry (BEAT) have what it takes to be a top stock pick for momentum investors? Let's find out.

BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know

BioTelemetry (BEAT) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session.

Is BioTelemetry (BEAT) Stock Outpacing Its Medical Peers This Year?

Is (BEAT) Outperforming Other Medical Stocks This Year?